ABSTRACT
Patients with cardiac implantable electronic devices undergoing radiotherapy (RT) are prone to the risk of device failure. Guidelines and manufacturer's instructions are lacking practical recommendations for cumulative radiation doses to pacemakers or implantable cardioverter defibrillators. The present case demonstrates the effect of RT of a Merkel cell carcinoma near the location of a cardiac resynchronization therapy pacemaker. Despite guideline recommendations, surgical relocation or de novo implantation of the device on the contralateral side was avoided to prevent the dissemination of tumour cells, inflammation, and wound healing complications. A total dose of 47.25 Gy applied in very close proximity to the cardiac resynchronization therapy pacemaker was carried out safely without jeopardizing the patient and any device malfunction during and after treatment within >1.5 years of follow-up period. The present case demonstrates that high-dose RT near to a cardiac resynchronization therapy device can be carried out safely. Special precautions during RT as well as close device follow-up interrogations are mandatory. Large-scale studies are needed for the true frequency of adverse events.
ABSTRACT
BACKGROUND AND AIM: The complexity and success rate of right atrial flutter ablation is highly dependent on anatomical structures. METHODS: The study comprised 35 consecutive patients (33-77 years old; 30 men) who underwent ablation of typical atrial flutter. The linear ablation line was measured offline as a surrogate for the cavotricuspid isthmus (CTI) length with the help of a three-dimensional mapping and navigation system (Ensite™). Biophysical parameters, such as total radiofrequency (RF) energy and time of the ablation procedure, were analysed to test the hypothesis that any of these variables show a correlation with the length of the ablation line. RESULTS: Bidirectional isthmus block was achieved in all cases. The isthmus length had a mean value of 32 ± 12 mm with a range of 14-57 mm. The linear regression between the CTI length and the total RF energy was not significant. There was no significant difference in energy (32.281 ± 25.587 vs. 37.136 ± 24.250 W-s, p = NS) or in the total ablation time (759 ± 646 vs. 802 ± 533 s, p = NS) between the group with short (< 29 mm; n = 17) vs. long CTI (≥ 29 mm, n = 18). When comparing different ablation technologies, total RF energy delivered with 8-mm catheter technology (group I) was significantly lower than in patients with cross over from 8-mm to cooled ablation technology (group III) (29.615 ± 12.331 vs. 62.674 ± 28.735 W-s, p = 0.01). The same was true for the comparison between cooled ablation technology (group II) and group III (19.879 ± 13.669 vs. 62.674 ± 28.735 W-s, p = 0.002). CONCLUSIONS: The length of the CTI as measured with help of a three-dimensional mapping system may reflect only a weak indicator for the complexity of flutter ablation procedures. The thickness of musculature and specific anatomy of the CTI seem to be the main challenges in performing a linear ablation to achieve bidirectional block.
Subject(s)
Anatomic Variation , Atrial Flutter/pathology , Catheter Ablation/methods , Heart Atria/pathology , Adult , Aged , Atrial Flutter/surgery , Female , Heart Atria/surgery , Humans , Male , Middle AgedABSTRACT
BACKGROUND: Previous trials have demonstrated clinically significant and durable reductions in arterial pressure from baroreflex activation therapy (BAT), resulting from electrical stimulation of the carotid sinus using a novel implantable device. A second-generation system for delivering BAT, the Barostim neo™ system, has been designed to deliver BAT with a simpler device and implant procedure. METHODS: BAT, delivered with the advanced system, was evaluated in a single-arm, open-label study of patients with resistant hypertension, defined as resting systolic blood pressure (SBP) ≥140 mm Hg despite treatment with ≥3 medications, including ≥1 diuretic. Stable medical therapy was required for ≥4 weeks before establishing pretreatment baseline by averaging two SBP readings taken ≥24 hours apart. RESULTS: Thirty patients enrolled from seven centers in Europe and Canada. From a baseline of 171.7 ± 20.2/99.5 ± 13.9 mm Hg, arterial pressure decreased by 26.0 ± 4.4/12.4 ± 2.5 mm Hg at 6 months. In a subset (n = 6) of patients with prior renal nerve ablation, arterial pressure decreased by 22.3 ± 9.8 mm Hg. Background medical therapy for hypertension was unchanged during follow-up. Three minor procedure-related complications occurred within 30 days of implant. All complications resolved without sequelae. CONCLUSION: BAT delivered with the second-generation system significantly lowers blood pressure in resistant hypertension with stable, intensive background medical therapy, consistent with studies of the first-generation system for electrical activation of the baroreflex, and provides a safety profile comparable to a pacemaker.
